Peringatan Keamanan

Toxicity information regarding faricimab is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as conjunctival hemorrhage. Symptomatic and supportive measures are recommended. Due to its mechanism of action, faricimab may pose a risk to reproductive capacity.L40026

Faricimab

DB15303

biotech approved investigational

Deskripsi

Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).A225985, A225990, A225995 Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies such as aflibercept and ranibizumab solely target VEGF-A. However, another set of factors, the Tie/Ang axis, comprising the transmembrane Tie-2 receptor and its soluble ligands Ang-1 and Ang-2, has been shown to play critical roles in mediating VEGF-A-induced NV.A225985, A225990, A225995 Faricimab is an IgG1-derived bispecific antibody capable of simultaneously binding to and depleting VEGF-A and Ang-2, which has been developed to improve therapeutic efficacy, especially in patients that respond poorly to anti-VEGF-A monotherapy.A225985, A225990, A225995, A226000, A226005, A226010

Faricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc.L40026 It received subsequent approval for the same indications in Canada in May 2022.L42305 In July 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended faricimab be granted marketing authorization for the treatment of neovascular age-related macular degeneration and diabetic macular edema.L43085

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Faricimab has an estimated mean apparent systemic half-life of 7.5 days.[L40026]
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Faricimab unbound plasma Cmax are estimated to be 0.23 ± 0.07 and 0.22 ± 0.07 ?g/mL in nAMD and DME patients, respectively; these plasma levels are achieved approximately two days post-dose (Tmax). Following repeated intravitreal administration on a q8w schedule, mean plasma trough free faricimab concentrations are predicted to be 0.002-0.003 ?g/mL. No accumulation is expected in either the vitreal fluid or plasma.L40026

Metabolisme

Faricimab metabolism has not been fully characterized; as an antibody, faricimab is expected to be catabolized like endogenous immunoglobulins.L40026

Rute Eliminasi

Faricimab elimination has not been fully characterized; faricimab may be excreted renally following its breakdown into smaller peptides and amino acids through cellular catabolism.L40026

Interaksi Obat

0 Data
Tidak ada data.

Target Protein

Vascular endothelial growth factor A, long form VEGFA
Angiopoietin-2 ANGPT2

Referensi & Sumber

Synthesis reference: Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G: Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016 Nov 2;8(11):1265-1288. doi: 10.15252/emmm.201505889.
Artikel (PubMed)
  • PMID: 26113211
    Campochiaro PA: Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015 Nov;49:67-81. doi: 10.1016/j.preteyeres.2015.06.002. Epub 2015 Jun 23.
  • PMID: 32785136
    Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM: Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab. Cells. 2020 Aug 10;9(8). pii: cells9081869. doi: 10.3390/cells9081869.
  • PMID: 27742718
    Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G: Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016 Nov 2;8(11):1265-1288. doi: 10.15252/emmm.201505889. Print 2016 Nov.
  • PMID: 31695160
    Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A: Faricimab: expanding horizon beyond VEGF. Eye (Lond). 2020 May;34(5):802-804. doi: 10.1038/s41433-019-0670-1. Epub 2019 Nov 6.
  • PMID: 21690412
    Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, Schwaiger M, Stubenrauch KG, Sustmann C, Thomas M, Scheuer W, Klein C: Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92. doi: 10.1073/pnas.1019002108. Epub 2011 Jun 20.
  • PMID: 31175342
    Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI: Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. doi: 10.1038/s41573-019-0028-1.

Contoh Produk & Brand

Produk: 3 • International brands: 0
Produk
  • Vabysmo
    Solution • 6 mg / 0.05 mL • Intravitreal • Canada • Approved
  • Vabysmo
    Injection, solution • 6 mg/0.05mL • Intravitreal • US • Approved
  • Vabysmo
    Injection, solution • 120 mg/ml • Intravitreal • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul